DUPIXENT®

WELCOME BACK TO A LIFE WITH SUSTAINED CONTROL IN SEVERE CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSwNP)¹

DUPIXENT sustained results across measures through to Week 52 vs placebo¹

Give eligible patients results they can experience with DUPIXENT¹

DUPIXENT is the first biologic that directly targets interleukin‑4 (IL-4) and IL-13 signalling to reduce type 2 inflammation in adults with severe CRSwNP^1–3

Indication

DUPIXENT is indicated as an add‑on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery does not provide adequate disease control.¹

ABBREVIATIONS
CRSwNP, chronic rhinosinusitis with nasal polyps; IL-4/13, interleukin-4/13; NP, nasal polyps

REFERENCES

1. DUPIXENT (dupilumab) Summary of Product Characteristics (UK).
2. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15(1):35‑50.
3. Schleimer RP. Annu Rev Pathol. 2017;12:331‑57.
4. Bachert C, et al. Lancet. 2019;394(10209):1638-50.